Iressa Follow-up Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00357734

Recruitment Status : Completed

First Posted : July 27, 2006

Results First Posted : June 23, 2016

Last Update Posted : August 30, 2016

Sponsor:

Information provided by (Responsible Party):

AstraZeneca

Study Description

Brief Summary:

The purpose of this study is to assess the long-term safety profile and the secondary objective to estimate clinical benefit of ZD1839 (gefitinib).

Condition or disease	Intervention/treatment	Phase
Lung Cancer Breast Cancer	Drug: Gefitinib	Phase 3

Study Design


Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	14 participants
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	Multicenter Open-label, Long-term Safety Trial of Treatment Extension With ZD1839 in Patients Who Have Been Treated in Other ZD1839 Clinical Trials.
Study Start Date :	January 2005
Actual Primary Completion Date :	May 2015
Actual Study Completion Date :	May 2015

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: Breast cancer Lung cancer

Drug Information available for: Gefitinib

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Gefitinib (ZD1839) ZD1839 at a daily dose of 250 mg or 500 mg depending on final dose in parent trial	Drug: Gefitinib ZD1839 at a daily dose of 250 mg or 500 mg depending on final dose in parent trial

Outcome Measures

Primary Outcome Measures :

Number of Serious Adverse Events (SAEs) [ Time Frame: Serious adverse events (SAEs) and non-serious AEs were collected from the start of study treatment until 30 days after the last dose of study treatment or 30 days after last visit (up to approximately 120 months) ]
Assessment of the long-term safety profile of ZD1839 therapy by assessing the incidence of adverse events. Any adverse events (AEs) and serious adverse events (SAEs) occurring during treatment and any SAEs occurring within 30 days after stopping the trial drug must be followed to resolution unless, in the investigator's opinion, the condition is unlikely to resolve because of the patient's underlying disease
Number of Serious Adverse Events (SAEs) Related to ZD1839 [ Time Frame: Serious adverse events (SAEs) and non-serious AEs were collected from the start of study treatment until 30 days after the last dose of study treatment or 30 days after last visit (up to approximately 120 months) ]
Assessment of the long-term safety profile of ZD1839 therapy by assessing the incidence of adverse events. Any adverse events (AEs) and serious adverse events (SAEs) occurring during treatment and any SAEs occurring within 30 days after stopping the trial drug must be followed to resolution unless, in the investigator's opinion, the condition is unlikely to resolve because of the patient's underlying disease.
Number of Other Adverse Events (AEs) [ Time Frame: Serious adverse events (SAEs) and non-serious AEs were collected from the start of study treatment until 30 days after the last dose of study treatment or 30 days after last visit (up to approximately 120 months) ]
Assessment of the long-term safety profile of ZD1839 therapy by assessing the incidence of adverse events. Any adverse events (AEs) and serious adverse events (SAEs) occurring during treatment and any SAEs occurring within 30 days after stopping the trial drug must be followed to resolution unless, in the investigator's opinion, the condition is unlikely to resolve because of the patient's underlying disease.
Number of Other Adverse Events (AEs) Related to ZD1839 [ Time Frame: Serious adverse events (SAEs) and non-serious AEs were collected from the start of study treatment until 30 days after the last dose of study treatment or 30 days after last visit (up to approximately 120 months) ]
Assessment of the long-term safety profile of ZD1839 therapy by assessing the incidence of adverse events. Any adverse events (AEs) and serious adverse events (SAEs) occurring during treatment and any SAEs occurring within 30 days after stopping the trial drug must be followed to resolution unless, in the investigator's opinion, the condition is unlikely to resolve because of the patient's underlying disease.

Secondary Outcome Measures :

Progression-free Survival (PFS) [ Time Frame: From randomization until progression or death (up to 120 months) ]
Objective disease progressing was assessed using the previous cancer response criteria in the parent ZD1839 trial: ie Southwest Oncology Group (SWOG) tumor response criteria, as a 50% increase or an increase of 10 cm2 (whichever is smaller) in the sum of products of all measurable lesions from the overall smallest sum observed (over baseline if no decrease) using the same techniques as baseline; Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase In the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Overall Survival (OS) [ Time Frame: From randomization until death (up to 120 months) ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years to 99 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Provision of written informed consent to participate in the trial.
Female or male aged 18 years and over.
Patients with previously diagnosed cancer who have been treated with ZD1839 in a parent ZD1839 clinical trial and may benefit from continuation

Exclusion Criteria:

Known severe hypersensitivity to ZD1839
Concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or St John's Wort.
Withdrawal from a parent ZD1839 trial because of tumor progress

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00357734

Locations


Germany
Research Site
Freiburg, Germany
Research Site
Gauting, Germany
Research Site
Großhansdorf, Germany
Research Site
Hemer, Germany
Research Site
Jena, Germany
Research Site
Minden, Germany
Research Site
Tübingen, Germany

Sponsors and Collaborators

AstraZeneca

Investigators


Study Director:	AstraZeneca Germany Medical Director, MD	AstraZeneca

More Information


Responsible Party:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00357734 History of Changes
Other Study ID Numbers:	1839IL/0555 D7913L00008
First Posted:	July 27, 2006 Key Record Dates
Results First Posted:	June 23, 2016
Last Update Posted:	August 30, 2016
Last Verified:	June 2016

Keywords provided by AstraZeneca:


lung cancer breast cancer

Additional relevant MeSH terms:


Gefitinib Antineoplastic Agents Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action

To Top